An Important Factor Driving the Next Generation Immunotherapies Market Is the Rising Cancer Prevalence Driving Growth In The Market
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Next Generation Immunotherapies Market Evolve From 2026 To 2030?
The next generation immunotherapies market has seen swift expansion in recent years. It is anticipated to expand from $150.12 billion in 2025 to $168.33 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. The increase observed in the past can be attributed to the rising global incidence of cancer, the early triumphs of immune checkpoint inhibitors, increased research and development investments in oncology, regulatory clearances for monoclonal antibodies, and a growing understanding of immuno-oncology treatments.
The market size for next generation immunotherapies is projected to experience substantial expansion over the upcoming years. This market is set to reach $262.82 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. Several factors during the forecast period are contributing to this growth, such as developments in next-generation antibody engineering, the widening scope of applications beyond cancer treatment, an increase in approvals for ADC-based therapies, the rise in biomarker-guided treatment choices, and a heightened need for effective and enduring therapies. Key trends anticipated during this period encompass the broadening of combination immunotherapy approaches, an increase in personalized cancer vaccines, the growing acceptance of bispecific antibodies, a greater emphasis on mitigating immune-related adverse effects, and accelerated clinical trial initiatives for solid tumors.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp
What Key Drivers Are Influencing The Growth Of The Next Generation Immunotherapies Market?
The rising prevalence of cancer is projected to stimulate the expansion of the next-generation immunotherapies market in the future. Cancer refers to a group of diseases typified by the uncontrolled multiplication and spread of abnormal cells throughout the body. The increasing occurrence of cancer is attributed to factors such as aging populations, changes in lifestyle, environmental exposures, and more effective detection methods. Next-generation immunotherapies offer advanced, targeted treatments that strengthen the body’s immune system to combat cancer, leading to enhanced effectiveness, durability, and personalized care. For instance, in July 2024, according to projections published by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are projected to increase for most types between 2023-2025 and 2038-2040, with rises ranging from less than 1% for breast cancer to 50% for eye cancer, while a smaller number of cancers are expected to see a decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Therefore, the growing prevalence of cancer is fueling the growth of the next-generation immunotherapies market.
Which Segment Areas Are Covered In The Next Generation Immunotherapies Market Analysis?
The next generation immunotherapies market covered in this report is segmented –
1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies
2) By Antibody-Drug Conjugates (ADCs): HER2-Targeted ADCs, CD30-Targeted ADCs, CD19-Targeted ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
How Are Trends Impacting The Next Generation Immunotherapies Market?
Leading firms within the next-generation immunotherapies market are concentrating on creating advanced treatments, including CAR T-cell therapy, for conditions like cancers, autoimmune diseases, and infectious diseases. This immunotherapy involves genetically engineering a patient’s T cells, which are immune cells, to carry chimeric antigen receptors (CARs). A notable example occurred in January 2025, when Immuneel Therapeutics Private Limited, an India-based cell and gene therapy startup, introduced Qartemi, recognized as India’s first CAR T-cell therapy. Intended for adult B-cell non-Hodgkin lymphoma, this treatment modifies a patient’s immune cells genetically to specifically target and eliminate cancer cells, providing a very effective and customized therapeutic choice. It offers fresh promise to patients unresponsive to standard treatments, with the added benefit of being more cost-effective compared to comparable international alternatives.
Which Global Companies Are Actively Competing In The Next Generation Immunotherapies Market?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.
Read the full next generation immunotherapies market report here:
Which Region Is Expected To Register The Fastest Growth In The Next Generation Immunotherapies Market?
North America was the largest region in the next-generation immunotherapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Next Generation Immunotherapies Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21231&type=smp
Browse Through More Reports Similar to the Global Next Generation Immunotherapies Market 2026, By The Business Research Company
Next Generation Gynecological Cancer Diagnostics Global Market Report
Breast Cancer Diagnostics Global Market Report
https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report
Oncology Companion Diagnostics Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
